JAN 23, 2018 6:06 AM PST

Enhancing Dendritic Cells to Fight Cancer

WRITTEN BY: Kara Marker

Scientists propose extracting dendritic cells and priming them to fight cancer before returning them to a patient as part of a new immunotherapy approach. From the Ecole Polytechnique Fédérale de Lausanne (EPFL), researchers are looking to maximize current cancer immunotherapy methods to be powerful and very accurate.

Two images of EVIR-engineered dendritic cells (green) capturing tumor antigens in exosomes (gold/red). Cell nuclei are colored blue. Credit: M. De Palma/EPFL

A vital part of the immune system, dendritic cells are antigen-presenting cells, which means they identify, bind, and bring proteins unique to foreign invaders to show killer T cells. As their name suggests, killer T cells are the ones who destroy tumor cells.

“Dendritic cells acquire immunogenic antigens from the tumor and directly display them on their own surface," explained Michele De Palma.

The new technique focuses on improving the way dendritic cells recognize tumor antigens. Researchers extract dendritic cells from a cancer patient, which are exposed to tumor antigens and injected back into the patient. In theory, this process prepares dendritic cells so they are more equipped to find and present antigens in the patient so killer T cells can destroy the tumor. In the past, scientists have had trouble with tumor cells (and their antigens) evading detection by the immune system.

This approach isn’t perfect. The antigens exposed to dendritic cells after their extraction from the cancer patient are not identical to the antigens the dendritic cells actually come into contact with in the body. This variance increases the risk of killer T cells not being properly activated to kill tumor cells.

In the new study published in Nature Methods, EPFL researchers offer a solution: extracellular vesicle-internalizing receptors (EVIR). These are artificial receptors that help dendritic cells “selectively and efficiently” identify and bind tumor antigens in the body to present to killer T cells.

Scientists inject EVIRs into the dendritic cell, where they recognize exosomal proteins. These are small vesicles within the cell that, in the context of cancer, are released by tumors and are rich with tumor antigens. In past studies, exosomal proteins have been associated with promoting metastasis, the spreading of a tumor to various tissues.

EVIRs essentially introduce tumor antigens from exosomes to dendritic cells so they can better target them. Palma says that this is an “unconventional route for antigen presentation to T cells."

"The EVIR technology can intercept a natural phenomenon - the release of exosomes from tumors - to the patient's benefit," explained first author Mario Leonardo Squadrito. "It exploits pro-tumoral exosomes as selective nanocarriers of tumor antigens, making them available to the immune system for cancer recognition and rejection."

Scientists from the study plan on investigating the relationship between EVIRs, dendritic cells, antigens, and exosomal proteins further. Additionally studies will have to be done before the new immunotherapy approach can be applied as a cancer treatment.

Source: Ecole Polytechnique Fédérale de Lausanne

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
DEC 14, 2020
Genetics & Genomics
tRNA Plays a Role in the Immune Response to Stroke
DEC 14, 2020
tRNA Plays a Role in the Immune Response to Stroke
At one time, researchers knew that various forms of RNA served a few different critical roles in the creation of protein ...
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
FEB 09, 2021
Immunology
Putting the Kibosh on HIV's Stealth Tactics
FEB 09, 2021
Putting the Kibosh on HIV's Stealth Tactics
The human immunodeficiency virus or HIV is always one step of the immune system, a tactic that makes it impossible to co ...
MAR 23, 2021
Immunology
Assay Detects Antibodies in Asymptomatic COVID Carriers
MAR 23, 2021
Assay Detects Antibodies in Asymptomatic COVID Carriers
It is estimated that around one in five people infected with SARS-CoV-2 will not show any infection symptoms. Some of th ...
APR 03, 2021
Cancer
New factor plays a key role in immune response
APR 03, 2021
New factor plays a key role in immune response
In a study published recently in Science Immunology, WEHI’s Professor Stephen Nutt, Dr. Michael Chopin, and Mr. Sh ...
APR 19, 2021
Cell & Molecular Biology
Insight Into the Molecular Basis of Rheumatoid Arthritis
APR 19, 2021
Insight Into the Molecular Basis of Rheumatoid Arthritis
New research has shown how variants in an immune gene can lead to a high risk of developing the autoimmune disorder rheu ...
Loading Comments...